|
Leader
|
|
|
00000nz a2200037n 45 0 |
|
001
|
|
|
WKP|Q60959189
(VIAF cluster)
(Authority/Source Record)
|
|
003
|
|
|
WKP |
|
005
|
|
|
20241221010847.0 |
|
008
|
|
|
241221nneanz||abbn n and d |
|
035
|
|
|
‡a
(WKP)Q60959189
|
|
024
|
|
|
‡a
0000-0002-6020-6962
‡2
orcid
|
|
035
|
|
|
‡a
(OCoLC)Q60959189
|
|
100
|
0 |
|
‡a
Javier Vaquero
‡c
researcher ORCID ID = 0000-0002-6020-6962
‡9
en
|
|
375
|
|
|
‡a
1
‡2
iso5218
|
|
400
|
0 |
|
‡a
Javier Vaquero
‡c
onderzoeker
‡9
nl
|
|
670
|
|
|
‡a
Author's Activation of the nuclear receptor FXR enhances hepatocyte chemoprotection and liver tumor chemoresistance against genotoxic compounds.
|
|
670
|
|
|
‡a
Author's Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta.
|
|
670
|
|
|
‡a
Author's Cisplatin-induced chemoresistance in colon cancer cells involves FXR-dependent and FXR-independent up-regulation of ABC proteins.
|
|
670
|
|
|
‡a
Author's Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition.
|
|
670
|
|
|
‡a
Author's E-cadherin, guardian of liver physiology.
|
|
670
|
|
|
‡a
Author's Epithelial-mesenchymal transition in cholangiocarcinoma: From clinical evidence to regulatory networks.
|
|
670
|
|
|
‡a
Author's Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).
|
|
670
|
|
|
‡a
Author's Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.
|
|
670
|
|
|
‡a
Author's FXR-dependent and -independent interaction of glucocorticoids with the regulatory pathways involved in the control of bile acid handling by the liver.
|
|
670
|
|
|
‡a
Author's IGF2/IR/IGF1R pathway in tumor cells and myofibroblasts mediates resistance to EGFR inhibition in cholangiocarcinoma.
|
|
670
|
|
|
‡a
Author's Involvement of UDP-Glucuronosyltransferases and Sulfotransferases in the Excretion and Tissue Distribution of Resveratrol in Mice
|
|
670
|
|
|
‡a
Author's Loss of ezrin in human intrahepatic cholangiocarcinoma is associated with ectopic expression of E-cadherin.
|
|
670
|
|
|
‡a
Author's MiRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation.
|
|
670
|
|
|
‡a
Author's No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors.
|
|
670
|
|
|
‡a
Author's Role of ErbB/HER family of receptor tyrosine kinases in cholangiocyte biology.
|
|
670
|
|
|
‡a
Author's Role of the PDZ-scaffold protein NHERF1/EBP50 in cancer biology: from signaling regulation to clinical relevance.
|
|
670
|
|
|
‡a
Author's Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance
|
|
670
|
|
|
‡a
Author's Unveiling resistance mechanisms to EGFR inhibitors in cholangiocarcinoma
|
|
670
|
|
|
‡a
Author's Up-regulation of FXR isoforms is not required for stimulation of the expression of genes involved in the lack of response of colon cancer to chemotherapy.
|
|
909
|
|
|
‡a
(orcid) 0000000260206962
‡9
1
|
|
919
|
|
|
‡a
lossofezrininhumanintrahepaticcholangiocarcinomaisassociatedwithectopicexpressionofecadherin
‡A
Loss of ezrin in human intrahepatic cholangiocarcinoma is associated with ectopic expression of E-cadherin.
‡9
1
|
|
919
|
|
|
‡a
expressionofslc22a1variantsmayaffecttheresponseofhepatocellularcarcinomaandcholangiocarcinomatosorafenib
‡A
Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.
‡9
1
|
|
919
|
|
|
‡a
fxrdependentandindependentinteractionofglucocorticoidswiththeregulatorypathwaysinvolvedinthecontrolofbileacidhandlingbytheliver
‡A
FXR-dependent and -independent interaction of glucocorticoids with the regulatory pathways involved in the control of bile acid handling by the liver.
‡9
1
|
|
919
|
|
|
‡a
igf2irigf1rpathwayintumorcellsandmyofibroblastsmediatesresistancetoegfrinhibitionincholangiocarcinoma
‡A
IGF2/IR/IGF1R pathway in tumor cells and myofibroblasts mediates resistance to EGFR inhibition in cholangiocarcinoma.
‡9
1
|
|
919
|
|
|
‡a
involvementofudpglucuronosyltransferasesandsulfotransferasesintheexcretionandtissuedistributionofresveratrolinmice
‡A
Involvement of UDP-Glucuronosyltransferases and Sulfotransferases in the Excretion and Tissue Distribution of Resveratrol in Mice
‡9
1
|
|
919
|
|
|
‡a
mirna506promotesprimarybiliarycholangitislikefeaturesincholangiocytesandimmuneactivation
‡A
MiRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation.
‡9
1
|
|
919
|
|
|
‡a
unveilingresistancemechanismstoegfrinhibitorsincholangiocarcinoma
‡A
Unveiling resistance mechanisms to EGFR inhibitors in cholangiocarcinoma
‡9
1
|
|
919
|
|
|
‡a
upregulationoffxrisoformsisnotrequiredforstimulationoftheexpressionofgenesinvolvedinthelackofresponseofcoloncancertochemotherapy
‡A
Up-regulation of FXR isoforms is not required for stimulation of the expression of genes involved in the lack of response of colon cancer to chemotherapy.
‡9
1
|
|
919
|
|
|
‡a
expertconsensusdocumentcholangiocarcinomacurrentknowledgeandfutureperspectivesconsensusstatementfromtheeuropeannetworkforthestudyofcholangiocarcinomaenscca
‡A
Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).
‡9
1
|
|
919
|
|
|
‡a
activationofthenuclearreceptorfxrenhanceshepatocytechemoprotectionandlivertumorchemoresistanceagainstgenotoxiccompounds
‡A
Activation of the nuclear receptor FXR enhances hepatocyte chemoprotection and liver tumor chemoresistance against genotoxic compounds.
‡9
1
|
|
919
|
|
|
‡a
characterizationoftheroleofabcg2asabileacidtransporterinliverandplacenta
‡A
Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta.
‡9
1
|
|
919
|
|
|
‡a
cisplatininducedchemoresistanceincoloncancercellsinvolvesfxrdependentandfxrindependentupregulationofabcproteins
‡A
Cisplatin-induced chemoresistance in colon cancer cells involves FXR-dependent and FXR-independent up-regulation of ABC proteins.
‡9
1
|
|
919
|
|
|
‡a
differentialactivationofthehumanfarnesoid10receptordependsonthepatternofexpressedisoformsandthebileacidpoolcomposition
‡A
Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition.
‡9
1
|
|
919
|
|
|
‡a
ecadheringuardianofliverphysiology
‡A
E-cadherin, guardian of liver physiology.
‡9
1
|
|
919
|
|
|
‡a
nocorrelationbetweentheexpressionoffxrandgenesinvolvedinmultidrugresistancephenotypeofprimarylivertumors
‡A
No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors.
‡9
1
|
|
919
|
|
|
‡a
epithelialmesenchymaltransitionincholangiocarcinomafromclinicalevidencetoregulatorynetworks
‡A
Epithelial-mesenchymal transition in cholangiocarcinoma: From clinical evidence to regulatory networks.
‡9
1
|
|
919
|
|
|
‡a
roleoferbbherfamilyofreceptortyrosinekinasesincholangiocytebiology
‡A
Role of ErbB/HER family of receptor tyrosine kinases in cholangiocyte biology.
‡9
1
|
|
919
|
|
|
‡a
roleofthepdzscaffoldproteinnherf1ebp50incancerbiologyfromsignalingregulationtoclinicalrelevance
‡A
Role of the PDZ-scaffold protein NHERF1/EBP50 in cancer biology: from signaling regulation to clinical relevance.
‡9
1
|
|
919
|
|
|
‡a
signallingnetworksincholangiocarcinomamolecularpathogenesistargetedtherapiesanddrugresistance
‡A
Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance
‡9
1
|
|
946
|
|
|
‡a
b
‡9
1
|
|
996
|
|
|
‡2
ISNI|0000000059588102
|
|
996
|
|
|
‡2
LC|n 84155407
|
|
996
|
|
|
‡2
BNC|981058618320706706
|
|
996
|
|
|
‡2
LC|no2018103615
|
|
996
|
|
|
‡2
BNE|XX992059
|
|
996
|
|
|
‡2
BNE|XX1179131
|
|
996
|
|
|
‡2
ISNI|0000000060511049
|
|
996
|
|
|
‡2
ISNI|0000000121434199
|
|
996
|
|
|
‡2
SUDOC|143375113
|
|
996
|
|
|
‡2
BIBSYS|10001693
|
|
996
|
|
|
‡2
BNE|XX1027336
|
|
997
|
|
|
‡a
0 0 lived 0 0
‡9
1
|
